Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.59 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.54 |
| ▸ | PAM | P19021 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | NAAA | Q02083 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 2/20 | 0.46 |
| ▸ | CES1 | P23141 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6890027 | 1.00 | DGKA (0.59) | DGKASOAT1PAMLMNAMAPT | |
| SCHEMBL382296 | 1.00 | DGKA (0.59) | DGKASOAT1PAMLMNAMAPT | |
| SCHEMBL27396784 | 1.00 | DGKA (0.59) | DGKASOAT1PAMLMNAMAPT | |
| Hydrochloric Acid SCHEMBL27619222 | 0.96 | SOAT1 (0.54) | DGKASOAT1PAMLMNAMAPT | |
| SCHEMBL6643452 | 0.94 | SOAT1 (0.61) | DGKASOAT1PAMLMNAMAPT | |
| SCHEMBL20503311 | 0.92 | SOAT1 (0.58) | DGKASOAT1PAMLMNAMAPT | |
| SCHEMBL381506 | 0.92 | SOAT1 (0.64) | DGKASOAT1PAMLMNAMAPT | |
| SCHEMBL28005099 | 0.90 | SOAT1 (0.56) | DGKASOAT1PAMMAPTTSHR | |
| SCHEMBL464534 | 0.90 | FAAH (0.62) | DGKASOAT1LMNAMAPTTSHR | |
| SCHEMBL8968847 | 0.90 | FAAH (0.62) | DGKASOAT1LMNAMAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109640965-A | Compositions and methods for treating irritable bowel syndrome | 塞尔利克斯生物私人有限公司 | 2019-04-16 | — | — | CN | disclosed |
| US-20100129436-A1 | SUBTANCES FOR THE PROTECTION OF CELLS AND/OR TISSUES | LOSEL RALF | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100129436-A1 | SUBTANCES FOR THE PROTECTION OF CELLS AND/OR TISSUES | CTSA, BCL2, BAX | DGKA 2070/4885SOAT1 4091/4885PAM 4857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.